273 related articles for article (PubMed ID: 2389942)
1. [Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
Nagahata T; Shibasaki C; Ishii T; Uchida T; Arakawa M; Kusama K; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1437-45. PubMed ID: 2389942
[TBL] [Abstract][Full Text] [Related]
2. [Experimental combination chemotherapy of YNK01, a novel analog of cytarabine, with other antitumor agents].
Uchida T; Nagahata T; Arakawa M; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1990 Jul; 17(7):1351-6. PubMed ID: 2114829
[TBL] [Abstract][Full Text] [Related]
3. [A case of complete remission from acute unclassified leukemia achieved by using a prodrug of ara C, stearyl-ara-CMP (YNK01)].
Nishikawa M; Morita K; Komada F; Uemura Y; Kageyama S; Minami N; Deguchi K; Shirakawa S
Gan No Rinsho; 1990 Oct; 36(12):2204-9. PubMed ID: 2232191
[TBL] [Abstract][Full Text] [Related]
4. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR
Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392
[TBL] [Abstract][Full Text] [Related]
5. [Phase I study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate)].
Fukuoka M; Miyazaki T; Yoshida Y; Hattori M; Niitani H; Nakamura T; Hirota Y; Ohta K; Tanaka M; Suzuoki Y
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2213-9. PubMed ID: 2241185
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
Ueda T; Kamiya K; Urasaki Y; Wataya S; Kawai Y; Tsutani H; Sugiyama M; Nakamura T
Cancer Res; 1994 Jan; 54(1):109-13. PubMed ID: 8261429
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
[TBL] [Abstract][Full Text] [Related]
9. [A new antileukemic drug, cytarabine ocfosfate].
Tsukagoshi S
Gan To Kagaku Ryoho; 1993 Sep; 20(12):1877-83. PubMed ID: 8379682
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of antitumor activity of 1-beta-D-arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine in murine tumors.
Furusawa S; Mian AM
Cancer Treat Rep; 1987 May; 71(5):441-6. PubMed ID: 3567967
[TBL] [Abstract][Full Text] [Related]
11. 1-beta-D-arabinofuranosylcytosine nucleotide inhibition of sialic acid metabolism in WI-38 cells.
Myers-Robfogel MW; Spataro AC
Cancer Res; 1980 Jun; 40(6):1940-3. PubMed ID: 7371029
[TBL] [Abstract][Full Text] [Related]
12. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
Riva CM; Rustum YM
Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate: an orally active derivative of 1-beta-D-arabinofuranosylcytosine.
Kodama K; Morozumi M; Saitoh K; Kuninaka A; Yoshino H; Saneyoshi M
Jpn J Cancer Res; 1989 Jul; 80(7):679-85. PubMed ID: 2507491
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tumor cell growth in vitro and in vivo by 1-beta-D-arabinofuranosylcytosine entrapped within phospholipid vesicles.
Mayhew E; Papahadjopoulos D; Rustum YM; Dave C
Cancer Res; 1976 Dec; 36(12):4406-11. PubMed ID: 187321
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.
Schleyer E; Braess J; Ramsauer B; Unterhalt M; Kaufmann C; Wilde S; Schüssler M; Hiddemann W
Leukemia; 1995 Jun; 9(6):1085-90. PubMed ID: 7596174
[TBL] [Abstract][Full Text] [Related]
16. 1-beta-D-arabinofuranosylcytosine conjugates of thioether phospholipids as a new class of potential antitumor drugs.
Hong CI; Kirisits AJ; Buchheit DJ; Nechaev A; West CR
Cancer Drug Deliv; 1986; 3(2):101-13. PubMed ID: 3708534
[TBL] [Abstract][Full Text] [Related]
17. [Phase II study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate) on hematological malignancies].
Tatsumi N; Yamada K; Ohshima T; Nakamura T; Ohno R; Masaoka T; Kimura I; Kimura K
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2387-95. PubMed ID: 2260876
[TBL] [Abstract][Full Text] [Related]
18. [Antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) in P 388 leukemic cell bearing mice].
Watanabe A; Kuriyama H; Kiyota T
Gan To Kagaku Ryoho; 1996 Feb; 23(3):291-6. PubMed ID: 8712821
[TBL] [Abstract][Full Text] [Related]
19. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
Taub JW; Huang X; Ge Y; Dutcher JA; Stout ML; Mohammad RM; Ravindranath Y; Matherly LH
Cancer Res; 2000 Nov; 60(22):6421-6. PubMed ID: 11103808
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of 2'-deoxy-2'-methylidenecytidine, a new 2'-deoxycytidine derivative.
Yamagami K; Fujii A; Arita M; Okumoto T; Sakata S; Matsuda A; Ueda T; Sasaki T
Cancer Res; 1991 May; 51(9):2319-23. PubMed ID: 2015596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
